RxDoctor Payments Data

Sayed Hussain, MD

Interventional Cardiology · Winter Park, FLNPI 1093755308

Payments from drug & device makers

$58,109in general payments, 2019–2025

Across 793 payments — averaging $73.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$25K
  • Penumbra, Inc.$9K
  • Abiomed$5K
  • Abbott$3K
  • Johnson & Johnson$1K
  • Cvrx, Inc.$1K
  • plus $14K from 53 others

What the payments were for

  • Travel & lodging$22,60139%
  • Food & beverage$35,16461%
  • Education$3301%
  • Gifts$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)165$24,659
Penumbra, Inc.27$8,519
Abiomed65$5,421
Abbott34$2,772
Johnson & Johnson55$1,221
Cvrx, Inc.16$1,180
Inari Medical, Inc.6$990
Novartis46$854
Esperion Therapeutics, Inc.24$830
Merck26$826
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)40$821
Amgen44$808
Edwards Lifesciences7$761
Boehringer Ingelheim35$746
AstraZeneca37$727
Boston Scientific12$678
Kestra Medical Technology Services, Inc.14$527
Bayer18$459
Biotronik Inc.4$437
Livanova USA, Inc.6$407
Impulse Dynamics (USA) Inc.4$377
Siemens Medical Solutions USA, Inc.2$311
Biosense Webster, Inc.3$273
Angiodynamics, Inc.5$251
E.r. Squibb & Sons, L.L.C.12$247
Cardiovascular Systems Inc.4$233
Teleflex LLC1$183
Astellas Pharma US Inc6$177
Shockwave Medical, Inc1$176
Bard Peripheral Vascular, Inc.4$164
Amarin Pharma, Inc.9$145
Actelion Pharmaceuticals US, Inc.3$140
Bolton Medical Inc1$136
Intact Vascular, Inc.1$120
Novo Nordisk5$113
Scpharmaceuticals Inc.5$107
Getinge USA Sales, LLC2$107
Pfizer6$103
Tactile Systems Technology Inc6$102
Atricure, Inc.4$96
Cook Medical LLC1$95
Corindus Inc.1$94
Heartflow, Inc.3$90
Baxter Healthcare1$85
Philips North America LLC1$85
Endologix LLC1$84
Kiniksa Pharmaceuticals International, PLC2$59
Lexicon Pharmaceuticals, Inc.2$43
Arbor Pharmaceuticals, Inc.3$41
Alnylam Pharmaceuticals Inc.1$38
Lilly USA, LLC2$36
Kowa Pharmaceuticals America, Inc.2$26
Kiniksa Pharmaceuticals, Ltd.1$25
Bardy Diagnostics, Inc.2$24
Catheter Precision, Inc. FKA Ra Medical Systems, Inc.1$20
Acist Medical Systems, Inc.1$20
Sandoz1$16
Terumo Medical Corporation1$16
Gilead1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,109 in reported general payments places this provider in the 80th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$723,185
Medicare patients
1,125
Services billed
7,904

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban325$365,782
EntrestoSacubitril/Valsartan288$351,160
XareltoRivaroxaban209$218,831
Repatha SureclickEvolocumab150$140,142
FarxigaDapagliflozin Propanediol115$126,481
JardianceEmpagliflozin106$114,788
OzempicSemaglutide51$63,934
MounjaroTirzepatide42$50,894
VerquvoVericiguat35$33,718
BrilintaTicagrelor32$31,495
Ambrisentan11$30,215
WegovySemaglutide19$29,054
RybelsusSemaglutide21$25,533
Praluent PenAlirocumab30$23,544
VascepaIcosapent Ethyl37$23,474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$103$365,782325 claims
NovartisEntresto$854$351,160288 claims
Johnson & JohnsonXarelto$1,221$218,831209 claims
AstraZenecaFarxiga, Brilinta$727$157,976147 claims
Novo NordiskOzempic, Wegovy, Rybelsus$113$118,52191 claims
Boehringer IngelheimJardiance$746$114,788106 claims
Lilly USA, LLCMounjaro$36$50,89442 claims
MerckVerquvo$826$33,71835 claims
Esperion Therapeutics, Inc.Nexletol$830$20,26634 claims
AmgenCorlanor$808$16,58121 claims
Kowa Pharmaceuticals America, Inc.Livalo$26$6,20111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Winter Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →